Navigation Links
Phytomedics, Inc. Awarded QTDP Grant from U.S. Department of Health and Human Services
Date:11/9/2010

JAMESBURG, N.J., Nov. 9, 2010 /PRNewswire/ -- Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis.  PMI-001 is presently in Phase 2b/3 development.

(Logo: http://photos.prnewswire.com/prnh/20101109/NY97954LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20101109/NY97954LOGO)

Dr. Laurie Smaldone, Phytomedics President & CEO, commented: "We are very appreciative of the recognition and support provided by this award which we believe affirms that PMI-001 has the potential to address the significant unmet medical needs in Rheumatoid Arthritis."

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer.

PMI-001 is a novel, oral, disease-modifying, botanical drug for use in patients with Rheumatoid Arthritis (RA).  Three U.S. based, clinical trials, including a recently published and compelling 6 month Phase 2b/3 study, have demonstrated efficacy in the range of the intravenous biologic therapies, as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints with rapid onset of action (as early as 2 weeks), and the ability to halt joint erosions and narrowing (at 6 months), with an acceptable side effect profile.

Combined with the fact that this drug product is delivered as an oral dosage form, and behaves as a steroid-mimetic without corticosteroid side effects, makes PMI-001 a game changing therapeutic opportunity in RA, as well as in the wider autoimmune disease therapeutic category.

About Phytomedics

Phytomedics, Inc. is a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. Through its proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development. The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy.


'/>"/>
SOURCE Phytomedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
2. Medrium Awarded Electronic Health Record (EHR) Module Certification by Drummond Group
3. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
4. Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government
5. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
6. Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
8. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
9. NeoGenomics Awarded $374,000 in R&D Grants from the US Government
10. NuView Life Sciences Awarded Grants Under the Patient Protection and Affordable Care Act of 2010
11. ECRI Institute Awarded AHRQ Contract to Establish National Healthcare Horizon Scanning System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)...   Click here for supplemental information regarding ... the nation,s largest independent specialty pharmacy, announced today ... acquire Valley Campus Pharmacy, Inc., doing business as ... pharmacy that provides individualized patient care, based in ... 2015, TNH generated approximately $400 million in revenue. ...
(Date:4/28/2016)... 28, 2016 Research and Markets ... Surgery Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is ... the period 2016-2020. , ,The growing adoption of laser ... growth of the market. Lasers are used to treat ...
(Date:4/28/2016)... , April 28, 2016 ... George Phillips und Stephen ...    ArisGlobal®, ein führender Anbieter ... gab heute bekannt, dass neue Führungskräfte zum ... gestoßen sind, die vielfältige Erfahrungen mitbringen.  Dies ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... Over $60 Billion is spent annually on products for ... leading product review site for Toys, Tots, Pets & More (TTPM) announced the 15 ... Showcase at the Metropolitan Pavilion in New York City. , Chosen from a field ...
(Date:5/2/2016)... , ... May 02, 2016 , ... This week Omega ... its 2016 guest season which runs through October. Omega is offering a record 370 ... , “There has never been such widespread interest in or need for the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in Orange County, ... According to the research, which was published in the “Journal of the American Geriatrics ... about 5.4 million Americans have Alzheimer’s disease. The study found that dental problems may ...
(Date:5/2/2016)... RICHEY, Fla. (PRWEB) , ... ... ... and medical researchers report that many commonly used prescription medications, including anxiolytics, ... (1). To mitigate these risks, Novus Medical Detox Center —a leading ...
(Date:5/2/2016)... ... May 02, 2016 , ... The ... be held at the Bellagio Hotel in Las Vegas, NV from October 17–19, ... will be co-hosting the event. , This year’s conference will offer presentations ...
Breaking Medicine News(10 mins):